HOME > 研究業績詳細

研究業績詳細

頼高(齋藤) 朝子(ヨリタカ(サイトウ) アサコ)

研究テーマ Parkinson病
研究業績(論文) 【【学位論文】
1. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A. 1996;93:2696-2701.  

【他の英語論文】
2.Yoritaka A, Kobayashi Y, Hayashi T, Saiki S, Hattori N. Randomized double blind placebo controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study. Neurological Sciences Neurol Sci.2021
3. Kano M, Takanashi M, Oyama G, Yoritaka A, Hatano T, Shiba-Fukushima K, Nagai M, Nishiyama K, Hasegawa K, Inoshita T, Ishikawa KI, Akamatsu W, Imai Y, Bolognin S, Schwamborn JC, Hattori N. Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations. NPJ Parkinsons Dis. 2020 13;6(1):33.
4. Yoritaka A, Shimo Y, Hatano T, Hattori N. Motor/Non-motor Symptoms and Progression in Patients with Parkinson’s Disease: Prevalence and Risks in a Longitudinal Study. Parkinson’s disease 2020 20;2020:2735361.
5. Hayashida A, Li Y, Yoshino H, Daida K, Ikeda A, Ogaki K, Fuse A, Mori A, Takanashi M, Nakahara T, Yoritaka A, Tomizawa Y, Furukawa Y, Kanai K, Nakayama Y, Ito H, Ogino M, Hattori Y, Hattori T, Ichinose Y, Takiyama Y, Saito T, Kimura T, Aizawa H, Shoji H, Mizuno Y, Matsushita T, Sato M, Sekijima Y, Morita M, Iwasaki A, Kusaka H, Tada M, Tanaka F, Sakiyama Y, Fujimoto T, Nagara Y, Kashihara K, Todo H, Nakao K, Tsuruta K, Yoshikawa M, Hara H, Yokote H, Murase N, Nakamagoe K, Tamaoka A, Takamiya M, Morimoto N, Nokura K, Kako T, Funayama M, Nishioka K, Hattori N. The identified clinical features of Parkinson's disease in homo-, heterozygous and digenic variants of PINK1. Neurobiol Aging 2021; 97: 146.e1-146.
6. Hirayama M, Ito M, Minato T, Yoritaka A, LeBaron TW, Ohno K. Inhalation of hydrogen gas elevates urinary 8-hydroxy-2'-deoxyguanine in Parkinson's disease. Med Gas Res. 2019 9;8:144-149.
7. Yoritaka A, Ohtsuka C, Maeda T, et al. A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease. Movement Disord 2018;33:1505-1507
8. Yoritaka A, Hattori N. Differences between responders and non-responders in Parkinson’s disease. Advance in Parkinson’s disease 2017; DOI:10.4236 /apd.2017.62005
9. Ouma S, Fukae J, Fujioka S, Yamamoto S, Hatano T, Yoritaka A, Okuma Y, Kashihara KI, Hattori N, Tsuboi Y. The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study. Intern Med. 2017;56(15):1961-1966.
10. Yoritaka A, Mori H, Hattori N. Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease. Eur Neurol. 2016 Jun 29;76(1-2):35-39. 
11. Yoritaka A, et al. A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease: protocol and baseline characteristics. BMC Neurol 2016;16:66.
12. Yoritaka A, Fukae J, Hatano T, Hattori N. The Direct Cost of Parkinson Disease at Juntendo Medical University Hospital, Japan. Internal Medicine 2016; 55:113-9. 
13. Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K, Nagase M, Saito Y, Hattori N. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson’s disease. Parkinsonism & Related Disord 2015; 21:911-6.
14. Fukae J, Higuchi MA, Yanamoto S, Fukuhara K, Tsugawa J, Ouma S, Hatano T, Yoritaka A, Okuma Y, Kashihara K, Hattori N, Tsuboi Y. Utility of the Japanese version of the 9-item Wearing-off Questionnaire. Clin Neurol Neurosurg. 2015;134:110-5.
15. Fusegi K, Yoritaka A, Hattori N, Mori H. Automatic behavior in Parkinson's disease. Parkinsonism Relat Disord. 2015;21:84-5
16. Tsunemi Y, Takano T, Sato N, Yoritaka A, Ushimi T, Tamura N. Two cases of MERS associated with Legionnaires' Disease. Japanese Journal of Clinical Radiology 2014; 59: 202-209 12.
17. Fukae J, Ishikawa K, Hatano T, Yoritaka A, Takanashi M, Shimo Y, Tsugawa J, Tsuboi Y, Hattori N. Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson's disease patients. J Parkinsons Dis. 2014;4:499-505.
18. Hatano T, Hattori N, Kawanabe T, Terayama Y, Suzuki N, Iwasaki Y, Fujioka T; Yokukansan Parkinson’s Disease Study Group. An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease. J Neural Transm. 2014;121:275-81.
19. Yoritaka A, Shimo Y, Takanashi M, Fukae J, Hatano T, Nakahara T, Miyamato N, Urabe T, Hattori N. Motor and Non-Motor Symptoms of 1453 Patients with Parkinson’s Disease: Any Relationship with the Cumulative Doses of Anti-Parkinsonian Medications? J Neurological Disorders & Stroke. 2014;2 (2)
20. Yoritaka A. Sleep Disturbances in Parkinson’s Disease. J Neurological Disorders & Stroke. 2014;2 (2)
21. Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N. Pilot study of H2 therapy in Parkinson’s Disease: A Randomized Double-blind Placebo-controlled Trial. Move Disord 2013;28:836-839.
22. Yoritaka A, Shimo Y, Takanashi M, Fukae J, Hatano T, akahara T, Miyamato N, Urabe T Mori H, Hattori N. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism & Related Disord 2013;19:725-731.
23. Homma H, Yoritaka A, Hattori N, Kobayakawa T, Ikeda K.Clinical application of a card-type odor identification test to olfactory assessment in Parkinson's disease. Auris Nasus Larynx. 2013;40:173-6.
24. Shimada Y, Yoritaka A, Tanaka Y, Miyamoto N, Ueno Y, Hattori N, Takao U. Cerebral infarction in a young man using high-dose anabolic steroids. J Stroke Cerebrovasc Dis. 2012;21:906.
25. Yoritaka A, Shimo Y, Shimo Y, Inoue Y, Yoshino H, and Hattori N. Nonmotor Symptoms in Patients with PARK2 Mutations. Parkinson disease. 2011; 13: 473640.
26. Hatano T, Shimada Y, Kono A, Kubi SI, Yokoyama K, Yoritaka A, Nakahara T, Takanashi Y, Hattori N. Atypical Miller Fisher syndrome associated with glutamate receptor antibodies. BMJ Case reports 2011;
27. Kawanabe T, Yoritaka A, Shimura H, Oizumi H, Tanaka S. Hattori N. Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia. Progress in Neuropsychopharmacology & Biological Psychiatry 2010;34: 284-287. I
28. Hattori N, Wanga M, Taka H, Fujimura T, Yoritaka A, Kubo S, Mochizuki H. Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 2009;15 Suppl 1:S35-8.
29. Yoritaka A, Ohizumi H, Tanaka S, Hattori N. Parkinson's Disease with and without REM Sleep Behaviour Disorder: Are There Any Clinical Differences? Eur Neurol. 2009;61:164-170.
30. Tsutsumi S, Yasumoto Y, Ito M, Oishi H, Arai H, Yoritaka A. Atypical dural arteriovenous fistula associated with meningitis. Neurol Med Chir 2008; 48: 68-71.
31. Iizuka Y, YamashiroY, Suzuki M, Oizumi H, Yoritaka A, Tanaka S. Possible role local hypoxia in the de novo formation of dural and osteodural arteriovenous fistulas after encephalitis. Neuroradiol Journal 2008;21:698~703
32. Yoritaka A, Ohta K, Kishida S. Prevalence of neurological complications in Japanese patients with AIDS after the introduction of HAART. Clinical Neurology 2007;47:491-496.
33. Yoritaka A, Hishima T, Akagi K, Kishida S. Successful steroid treatment of acquired idiopathic partial hypohydrosis. J Dermatology 2006;33:265-267.
34. Yoritaka A, Ohta K, Akiyama H, Kishida S. Limbic encephalitis probably due to human herpes virus 6 after stem cell transplantation: A report of 3 cases. Neuroinfection 2005;10: 88-93.
35. Yoritaka A, Ohta K, Kishida S. Herpetic lumbosacral radiculoneuropathy in patients with patients with human immunodeficiency virus infection. Eur Neurol 2005;53:179-181.
36. Ohta K, Mori M, Yoritaka A, Okamoto K, Kishida S. Delayed ischemic stroke associated with methamphetamine use. J Emerg Med 28:165-7, 2005.
37. Arai N, Kishida S, Yoritaka A, Ohta K. Clinical investigation of the 8 cases with AIDS (acquired immunodeficiency syndrome)-associated progressive multifocal leukoencephalopathy (PML). Clinical Neurology 2005;45:89-95.
38. Sanaka M, Kishida S, Yoritaka A, Sasamura Y, Yamamoto T, Kuyama Y. Acute upper airway obstruction induced by an indwelling long intestinal tube: attention to the nasogastric tube syndrome. J Clin Gastroenterol 2004;38:913.
39. Yoritaka A, Yamada R, Ohta K, Kishida S. Successful treatment by fluconazole in a case of candida brain abscesses with renal and hepatic failure. Neuroinfection 2004; 9: 86-88
40. Yoritaka A, Sakai M, Ohta K, Kishida S. A case of Crow-Fukase syndrome showing improvement following excision and irradiation of bone lesions. Clinical Neurology 2004;44:369-371.
41. Ohta K, Yoritaka A, Sakamaki H, Kishida S. Immunosuppressive-associated encephalopathy in bone marrow transplant recipients. Brain and Nerve 2004; 56:395-401.
42. Yoritaka A, Arai N, Ohta K, Tsukamoto K, Kishida S. Single photon emission computed tomography of an acute focal demyelinating disease mimicking a brain tumor. Eur Neurol 2002; 48:222-223.
43. Yoritaka A, Tsukamoto T, Ohta K, Kishida S. A clinical study of pachymeningitis. Brain and Nerve 2002; 54:235-240.
44. Yoritaka A, Tsukamoto T, Ohta K, Kishida S. Facial myokymia associated with an isolated lesion of the facial nucleus. Acta Neurol Scand. 2001;104:182-184.
45. Yoritaka A, Nakagawa-Hattori Y, Hattori N, Kitahara A, Mizuno Y. A large Japanese family with Machado-Joseph disease: clinical and genetic analysis. Acta Neurol Scand. 1999; 99:241-244.
46. Miwa H, Yoritaka A, Mizuno Y. Hemifacial spasm in Parkinson's disease. Mov Disord. 1999;14:358-359.
47. Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, Kobayashi T, Yokochi M, Wang M, Yoritaka A, Kondo T, Kuzuhara S, Nakamura S, Shimizu N, Mizuno Y. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol. 1998;44:935-941.
48. Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, ElibolB, Brookes AJ, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, and Mizuno Y. Point Mutations (Thr240Arg and Ala311Stop) in the Parkin Gene. Biochem Biophys Res Commun 1998; 249: 754-758.
49. Matsumine H, Yamamura Y, Hattori N, Kobayashi T, Kitada T, Yoritaka A, Mizuno Y. A microdeletion of D6S305 in a family of autosomal recessive juvenile parkinsonism (PARK2). Genomics 1998; 49:143-146.
50. Yoritaka A, Hattori N, Yoshino H, Mizuno Y. Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. Short communication. J Neural Transm 1997;104:1313-1317.
51. Shimoda-Matsubayashi S, Hattori T, Matsumine H, Shinohara A, Yoritaka A, Mori H, Kondo T, Chiba M, Mizuno Y. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. Neurology. 1997;49:1257-1262.
52. Yoritaka A, Hatttori, T, Hattori Y, Kondo T, Mizuno Y. A 85 year old woman with the onset of progressive gait disturbance at 80 years of the age. Brain and Nerve 1997; 49:379-389.
53. Yoritaka A, Hattori N, Mori H, Kato K, Mizuno Y. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. J Neurol Sci. 1997;148:181-186.
54. Yoritaka A, Kogahara K, Yoshino H, Imai H, Mizuno Y. Clinical and neuroradiological studis on orbital myositis and Tolosa-Hunt syndrome.Clinical Neurology 1992; 32:593-599.
55. Yoritaka A, Sugiura K, Hiramatu, M, Baba M. A case of solitary thalamic abcess treated by sterotactic aspiration. Brain and Nerve 1990; 42: 749-753.

【日本語論文】
1. 頼高朝子 パーキンソン病とサプリメント Frontiers in Parkinson disease 2017;10:48-51
2. 頼高朝子 水素水の飲料効果 ドクターサロン 2017;61:13-16.
3. 頼高朝子 パーキンソン病における認知機能障害 cognitive impairment in Parkinson’s disease 老年期認知症研究会誌 2017;20:60-62.
4. 頼高朝子、布施木景子 統合失調症に合併したパーキンソン病症例の臨床的特徴 前方向的観察 初年度報告 平成28年度順天堂精神医学研究所紀要 2017.94-97.
5. 頼高朝子 Parkinson病に対する水素水の効果 Parkinson病治療に対する新しい取り組み 神経内科 2017;87:182-184.
6. 木原武士, 頼高朝子, 大栗優一, 杉山奈未, 宮澤仁朗. 簡便な認知機能テストとCDTを組み合わせたスクリーニングツールの開発 Progress in Medicine 2013:2:369-375. (本スクリーニングツールは各自治体で使用されています)
7. 中村利生,頼高朝子,角野禎子,鈴木宏昌,森秀生,須田耕一,田久保秀樹,水野美邦.歩行障害,眼球運動障害を主症状とした70歳男性.脳と神経 1997; 49:93-100.
8. 小島淳,頼高朝子,池辺慎一郎,中島八十一,水野美邦.視覚失認を呈した老年痴呆の1例:視覚情報処理過程からみた障害部位の推定.脳と神経 1996; 48:31-37.
9. 頼高朝子,平松まき,鵜飼宏,沢浦美奈子.Clonazepamが奏効した顎関節強直症.神経内科1991; 35:430-432.
10. 頼高朝子,平松まき,鵜飼宏,沢浦美奈子.右利き交叉性失語症に伴った再帰性発話.神経内科1991; 34:397-401.
【著書】
1. 頼高朝子 パーキンソン病 神経内科Clinical questions & Pearls III-31 サプリメントなどは治療効果ありますか?中外医学社 2019 291-295
2. 頼高朝子 パーキンソン病(第2版)II.病因 その他の因子 酸化ストレス 日本臨床増刊号 日本臨床社2018 167-173
3. 頼高朝子 訪問診療の診かた,考え方 6.パーキンソン病 大久保光夫編 中外医学社 2017東京
4. 頼高朝子、服部信孝 パーキンソン病・アルツハイマー型認知症 コエンザイムQ10の基礎と応用 コエンザイムQ協会編 丸善プラネット2015 97-104
5. 頼高朝子、森秀生: 認知症に有効な漢方薬について教えてください.どのような症状に対して使用するのか,また使用する際の注意点はどういったものがありますか?認知症診療Q&A92. 中島健二,和田健二編 中外医学社2012 218-221
6. 頼高朝子 患者さんは医師に何を望んでいるのか?あなたも名医!ここを押さえる!パーキンソン病診療. 服部信孝編 日本医事新報社2012 157-161
7. 頼高朝子.パーキンソン病診療役立ちコラム その1 パーキンソン病の情報とその活用.あなたも名医!ここを押さえる!パーキンソン病診療. 服部信孝編 日本医事新報社2012. 30.
8. 頼高朝子 パーキンソン病における睡眠障害への対応は?いきなり名医!パーキンソン病 Q&A. 服部信孝編. 日本医事新報社. 東京2009. 118-121
9. 頼高朝子, 望月秀樹. 感染症. 神経内科ハンドブック. 水野美邦編: 医学書院2009
10. 頼高朝子、服部信孝.パーキンソン病治療薬. 新薬展望. 政田幹夫、佐藤博、佐々木均編. 医薬ジャーナル. 大阪 2009.355-358
11. 頼高朝子,田中茂樹.在宅医学の対象別諸課題C 内科的疾患進行期の医学的管理2 神経難病 2)その他の神経難病.在宅医学 日本在宅医学会テキスト編集委員会編 メディカルビュー社,東京,2008. 355-358
12. 頼高朝子, 望月秀樹. 酸化的ストレス. パーキンソン病ハンドブック. 水野美邦編: 中外医学社2007. 294-305
12. 頼高朝子, 岸田修二. Acquired immunodeficiency syndrome (AIDS)にみられる脳疾患. 臨床医 29 増刊号: 2003. 758-761

研究者 教育活動